Evidence map›Paper›PMID 36633618›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2023

Pharmacokinetic profile of bitopertin, a selective GlyT

Imane Frouni, Dominique Bédard, Élodie Bourgeois-Cayer, Adjia Hamadjida, Fleur Gaudette, Francis Beaudry, Philippe Huot

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Imane FrouniDépartement de Pharmacologie et Physiologie, Université de Montréal, QC, Montreal, Canada.ORCID 0000-0001-6779-8713
Dominique BédardNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada.
Élodie Bourgeois-CayerNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada.
Adjia HamadjidaNeurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada.ORCID 0000-0001-9869-6752
Fleur GaudettePlateforme de Pharmacocinétique, Centre de Recherche du Centre Hospitalier de l', Université de Montréal, QC, Montreal, Canada.ORCID 0000-0003-0453-1522
Francis BeaudryDépartement de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.ORCID 0000-0001-5403-7333
Philippe HuotDépartement de Pharmacologie et Physiologie, Université de Montréal, QC, Montreal, Canada. philippe.huot@mcgill.ca.ORCID 0000-0002-5464-8334
Montreal Neurological Institute and Hospital · CACentre de Recherches sur la Cognition et l'Apprentissage · FRCentre Hospitalier de l’Université de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bitopertin, a selective glycine transporter 1 (GlyT

Indexed as

PiperazinesTandem Mass SpectrometryAdministration, OralAnimalsFemaleMaleRatsRats, Sprague-DawleySulfones(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanonePiperazinesSulfonesBitopertinGlycine transporter 1 inhibitorHPLC-HESI-MS/MSPharmacokineticsRat plasma

Identifiers

PMID36633618
OpenAlexW4315702519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.